中国临床药理学杂志2016，Vol.32Issue(6)：563-566,4.DOI:10.13699/j.cnki.1001-6821.2016.06.027
阿达木单抗治疗类风湿关节炎有效性和安全性的系统评价
Efficacy and safety of adalimumab in patients with rheumatoid arthritis：a Meta-analysis
吴凡 1盛晓燕 2马凌悦 1赵侠 1周颖 1崔一民2
作者信息
- 1. 北京大学第一医院药剂科，北京 100034
- 2. 北京大学 药学院 药事管理与临床药学系，北京 100191
- 折叠
摘要
Abstract
Objective To evaluate the efficacy and safety of adalimumab in patients with rheumatoid arthritis.Methods Electronic databases were searched: PubMed, EMbase, Cochrane library, CNKI, VIP and WanFang Date.The time range of retrieval is from database foundation to June 2015.The included randomized controlled trials were analyzed by the software RevMan 5.3.Results A total of 15 studies, 5209 patients were included.The efficacy of adalimumab with or without concomitant methotrexate ( MTX ) or disease -modifying anti -rheumatic drugs ( DMARDs) was better than placebo or MTX ( or DMARDs).There was no statistically significant difference in the occurrence of serious adverse events between the adalimumab group and the control group( P>0.05).Adalimumab appeared to increase the risk of serious infections compared with placebo or MTX ( or DMARDs).Conclusion Adalimumab is an effective drug for rheumatoid arthritis patients.The risk of adverse events and serious infection should be taken into account when adalimumab is selected.关键词
阿达木单抗/类风湿关节炎/有效性/安全性/Meta分析Key words
adalimumab/rheumatoid arthritis/efficacy/safety/Meta-analysis分类
医药卫生引用本文复制引用
吴凡,盛晓燕,马凌悦,赵侠,周颖,崔一民..阿达木单抗治疗类风湿关节炎有效性和安全性的系统评价[J].中国临床药理学杂志,2016,32(6):563-566,4.
